ESR1 and breast cancer: Triple-negative breast cancer (TNBC), marked by negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), is the most challenging subtype of BC due to its high heterogeneity and lack of effective target therapies (1).